Table 2.

Characteristics of the diseases in recipients of MLL-ELL-transduced BM cells

Mouse	Latency, days	WBC, 103/μl	Percent monocyte‡	RBC, 106/μl	PLT, 103/μl	Spleen weight, g	Ly5.2 WBC expressing Mac1, %
MSCVMLL-ELL# 3	126	73	44	4.4	162	0.37	88
MSCVMLL-ELL# 2	133	4	2	8.9	137	0.32	80
MSCVMLL-ELL# 5	150	17	55	9.4	225	0.35	76
MSCVMLL-ELL# 7	157	12	20	2.6	34	0.35	88
MSCVMLL-ELL# 8	167	33	48	6.2	142	0.65	86
MSCVMLL-ELL# 9	167	80	43	6.7	514	0.46	93
MSCVMLL-ELL# 1	182	36	30	1.35	25	0.39	94
MSCVMLL-ELL# 4	187	3.9	23	9.6	50	0.13	39
MSCVMLL-ELL# 10	189	185	60	1.7	129	0.52	94
MSCVMLL-ELL# 6	194	210	52	4.6	242	0.5	78
MSCVMLL-ELL mice*	165  ± 23	65  ± 744	38  ± 18	5.5  ± 3	166  ± 143	0.40  ± 0.14	82  ± 16
MIEMLL-ELL mice*	160  ± 32	25  ± 25	39  ± 26	4.0  ± 2	342  ± 280	0.46  ± 0.16	77  ± 27
MIE mice*	NA	8  ± 2.6	4.8  ± 2.8	9.4  ± 0.5	945  ± 124	0.090  ± 0.01†	16  ± 6

RBC, red blood cells; PLT, platelets; NA, not applicable; WBC, white blood cells. 

^*Values shown are the mean (±SD) from the 10 MSCVMLL-ELL mice, nine MIEMLL-ELL mice at the time of death, or the 10 control MIE mice bled 140 days after reconstitution. 

^†Spleen weight from age-matched mice. 

^‡These differential counts are an approximation as they were measured by the Cell-Dyn counter.